Commercial
Commercial, Wednesday 24 April 2024
Commercial
11:24Chair's Remarks
Afshan Rizvi Hussain, Managing Director, Global Rare Disease Lead, Havas Health
Commercial
11:25NIH as your technology development and commercialization partner
Commercial
11:45Health Technology Assessment of rare disease drugs: Exploring willingness to pay
Commercial
12:45Patient engagement strategy earlier in commercial planning
Commercial
13:05Meet the moment for advanced therapies: Past learnings, present state and collaborating for the future
Michael Lehmicke, Senior Vice President of Science and Industry Affairs, Alliance for Regenerative Medicine
Commercial
14:59Chair's Remarks
Afshan Rizvi Hussain, Managing Director, Global Rare Disease Lead, Havas Health
Commercial
15:20Commercializing in the ultra-orphan space: Unique challenges and opportunities
Zayd Daruwala, VP, Medical Strategy, Havas Life Rare
Jessica Klein, Rare Disease Awareness Marketer, KnoJAK Consulting
Lisa Jordan, Senior Vice President, Management Supervisor, Havas Life Rare
last published: 25/Apr/24 13:55
Commercial, Thursday 25 April 2024
Commercial
11:59Chair's Remarks
Commercial
12:00Preparing early for ex-US commercialisation – a patient access perspective
Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy
Commercial
12:20AI, insights and technology transformations within rare diseases
Commercial
12:40Transformative launch strategies: Commercializing orphan products for success
Moderator: Simone Seiter, Senior Partner, Simon-Kucher & Partners Strategy & Marketing Consultants GmbH
Grant Castor, SVP Commercial Strategy & Operations, Sentynl Therapeutics
Commercial
13:20Rescuing ‘orphaned’ drug programs & creating a viable commercial pathway for ultra-rare disease treatments
last published: 25/Apr/24 13:55
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events